JP2020517671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517671A5 JP2020517671A5 JP2019557637A JP2019557637A JP2020517671A5 JP 2020517671 A5 JP2020517671 A5 JP 2020517671A5 JP 2019557637 A JP2019557637 A JP 2019557637A JP 2019557637 A JP2019557637 A JP 2019557637A JP 2020517671 A5 JP2020517671 A5 JP 2020517671A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- antibody
- pharmaceutical composition
- seq
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023077997A JP2023113655A (ja) | 2017-04-28 | 2023-05-10 | 小児の障害を処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492031P | 2017-04-28 | 2017-04-28 | |
| US62/492,031 | 2017-04-28 | ||
| PCT/US2018/029579 WO2018200818A2 (en) | 2017-04-28 | 2018-04-26 | Method of treating pediatric disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077997A Division JP2023113655A (ja) | 2017-04-28 | 2023-05-10 | 小児の障害を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517671A JP2020517671A (ja) | 2020-06-18 |
| JP2020517671A5 true JP2020517671A5 (https=) | 2021-06-17 |
Family
ID=62455814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019557637A Withdrawn JP2020517671A (ja) | 2017-04-28 | 2018-04-26 | 小児の障害を処置する方法 |
| JP2023077997A Pending JP2023113655A (ja) | 2017-04-28 | 2023-05-10 | 小児の障害を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077997A Pending JP2023113655A (ja) | 2017-04-28 | 2023-05-10 | 小児の障害を処置する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200179486A1 (https=) |
| EP (1) | EP3615071A2 (https=) |
| JP (2) | JP2020517671A (https=) |
| KR (2) | KR20190141148A (https=) |
| CN (1) | CN110612120A (https=) |
| AR (1) | AR111491A1 (https=) |
| AU (2) | AU2018256840A1 (https=) |
| BR (1) | BR112019022268A2 (https=) |
| CA (1) | CA3061320A1 (https=) |
| IL (1) | IL270201B1 (https=) |
| MX (4) | MX2019012749A (https=) |
| TW (2) | TW202342102A (https=) |
| WO (1) | WO2018200818A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| JP7778567B2 (ja) * | 2019-04-17 | 2025-12-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 |
| CN115515435A (zh) * | 2020-02-11 | 2022-12-23 | 沃尔夫森医疗中心 | 有效治疗溃疡性结肠炎的方法 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| WO2025177055A1 (en) * | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Combination therapy for treating inflammatory bowel disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| WO1996024673A1 (en) | 1995-02-10 | 1996-08-15 | Leukosite, Inc. | Mucosal vascular addressins and uses thereof |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| NZ566263A (en) | 2002-05-24 | 2009-09-25 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
| KR100874292B1 (ko) | 2002-11-18 | 2008-12-18 | 케모센트릭스 | 아릴 술폰아마이드 |
| WO2006026759A2 (en) | 2004-09-03 | 2006-03-09 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
| EP1948691A1 (en) | 2005-11-17 | 2008-07-30 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN |
| CN103382222B (zh) | 2009-03-20 | 2016-12-28 | 安姆根有限公司 | α-4-β-7异二聚体特异性拮抗剂抗体 |
| MX367097B (es) | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| HK1244229A1 (zh) * | 2015-02-26 | 2018-08-03 | F. Hoffmann-La Roche Ag | 治疗CROHN病的整联蛋白β7拮抗剂和方法 |
| AU2017234010B2 (en) * | 2016-03-14 | 2024-06-13 | Millennium Pharmaceuticals, Inc. | Methods of treating or preventing graft versus host disease |
-
2018
- 2018-04-26 AU AU2018256840A patent/AU2018256840A1/en not_active Abandoned
- 2018-04-26 EP EP18728257.9A patent/EP3615071A2/en active Pending
- 2018-04-26 KR KR1020197030615A patent/KR20190141148A/ko not_active Ceased
- 2018-04-26 US US16/608,895 patent/US20200179486A1/en active Pending
- 2018-04-26 MX MX2019012749A patent/MX2019012749A/es unknown
- 2018-04-26 BR BR112019022268-5A patent/BR112019022268A2/pt unknown
- 2018-04-26 JP JP2019557637A patent/JP2020517671A/ja not_active Withdrawn
- 2018-04-26 CN CN201880027856.4A patent/CN110612120A/zh active Pending
- 2018-04-26 WO PCT/US2018/029579 patent/WO2018200818A2/en not_active Ceased
- 2018-04-26 CA CA3061320A patent/CA3061320A1/en active Pending
- 2018-04-26 KR KR1020257028168A patent/KR20250134146A/ko active Pending
- 2018-04-27 AR ARP180101099A patent/AR111491A1/es not_active Application Discontinuation
- 2018-04-27 TW TW112126603A patent/TW202342102A/zh unknown
- 2018-04-27 TW TW107114371A patent/TWI811216B/zh active
-
2019
- 2019-10-24 MX MX2024003905A patent/MX2024003905A/es unknown
- 2019-10-24 MX MX2024003906A patent/MX2024003906A/es unknown
- 2019-10-24 MX MX2024012972A patent/MX2024012972A/es unknown
- 2019-10-27 IL IL270201A patent/IL270201B1/en unknown
-
2023
- 2023-05-10 JP JP2023077997A patent/JP2023113655A/ja active Pending
-
2025
- 2025-04-09 AU AU2025202525A patent/AU2025202525A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517671A5 (https=) | ||
| Ferrara et al. | Anakinra for treatment-resistant Kawasaki disease: evidence from a literature review | |
| Smolen et al. | Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial | |
| JP2014533279A5 (https=) | ||
| JP2014514346A5 (https=) | ||
| JP2022509358A5 (https=) | ||
| JP2017537105A5 (https=) | ||
| JP2014511844A5 (https=) | ||
| JP2019530713A5 (https=) | ||
| JP2017079785A5 (https=) | ||
| JP2012067116A5 (https=) | ||
| JP2016530280A5 (https=) | ||
| JP2014515763A5 (https=) | ||
| JP2019534891A5 (https=) | ||
| JP2015172060A5 (https=) | ||
| JP2008536855A5 (https=) | ||
| WO2022052874A1 (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| JP2020523384A5 (https=) | ||
| McCormack et al. | Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease | |
| Davis et al. | Clinical development of siltuximab | |
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| JP2023510199A5 (https=) | ||
| Morel | Infection prevention and vaccination in the rheumatic diseases | |
| JP2021528399A5 (https=) | ||
| JP2025526402A5 (https=) |